Common Contracts
2 similar Agreement and Plan of Merger contracts by Lantheus Holdings, Inc., Progenics Pharmaceuticals Inc
AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER AMONG LANTHEUS HOLDINGS, INC., PLATO MERGER SUB, INC. AND PROGENICS PHARMACEUTICALS, INC. DATED AS OF FEBRUARY 20, 2020Agreement and Plan of Merger • February 20th, 2020 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Amended and Restated Agreement and Plan of Merger (this “Agreement”), dated as of February 20, 2020 (the “Execution Date”), among Lantheus Holdings, Inc., a Delaware corporation (“Parent”), Plato Merger Sub, Inc., a Delaware corporation and a wholly-owned Subsidiary of Parent (“Merger Sub”), and Progenics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), amends and restates in its entirety that certain Agreement and Plan of Merger (the “Original Merger Agreement”), dated as of October 1, 2019 (the “Original Execution Date”), among Parent, Merger Sub and the Company. Parent, Merger Sub and the Company are referred to individually as a “Party” and collectively as the “Parties”. Capitalized terms have the meanings given to them in Section 1.1.
AGREEMENT AND PLAN OF MERGER AMONG LANTHEUS HOLDINGS, INC., PLATO MERGER SUB, INC. AND PROGENICS PHARMACEUTICALS, INC. DATED AS OF OCTOBER 1, 2019Agreement and Plan of Merger • October 2nd, 2019 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • Delaware
This Agreement and Plan of Merger, dated as of October 1, 2019 (this “Agreement”), is made and entered into among Lantheus Holdings, Inc., a Delaware corporation (“Parent”), Plato Merger Sub, Inc., a Delaware corporation and a wholly-owned Subsidiary of Parent (“Merger Sub”), and Progenics Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Parent, Merger Sub and the Company are referred to individually as a “Party” and collectively as the “Parties”. Capitalized terms have the meanings given to them in Section 1.1.
